glp-1 gip and glucagon Glucagon-like peptide-1 Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP)

For patients on ACE inhibitors or ARBs, regular monitoring of serum creatinine and potassium levels is advised to catch any issues early

Retatrutide FDA Approval Timeline Phase 3 trials conclude: May 2026 NDA submission: Late 2026 (projected) FDA decision window: Q1Q2 2027 Read the full Retatrutide FDA roadmap (20262028) Safety Update & New Side Effects (Dysesthesia) While Retatrutides results are unprecedented, Phase 3 data identified a new safety signal not commonly seen with other GLP-1 drugs

Whats needed in order to fully implement GLP-1s as a treatment option for HS

NAION is sometimes referred to as an eye stroke because it occurs when blood flow to the optic nerve becomes restricted, damaging the nerve fibers responsible for transmitting visual information to the brain

The medication is still working